Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery.
Insulin therapy is the central component of treatment for type 1 and advanced type 2 diabetes; however, its narrow therapeutic window is associated with a risk of severe hypoglycemia. A glucose-responsive carrier that demonstrates consistent and slow basal insulin release under a normoglycemic condition and accelerated insulin release in response to hyperglycemia in real-time could offer effective blood glucose regulation with reduced risk of hypoglycemia. Here, we describe a poly(l-lysine)-derived biodegradable glucose-responsive cationic polymer for constructing polymer-insulin complexes for glucose-stimulated insulin delivery. The effects of the modification degree of arylboronic acid in the synthesized cationic polymer and polymer-to-insulin ratio on the glucose-dependent equilibrated free insulin level and the associated insulin release kinetics have been studied. In addition, the blood glucose regulation ability of these complexes and the associated glucose challenge-triggered insulin release are evaluated in type 1 diabetic mice.
['Wang|Jinqiang|J|', 'Wang|Zejun|Z|', 'Chen|Guojun|G|', 'Wang|Yanfang|Y|', 'Ci|Tianyuan|T|', 'Li|Hongjun|H|', 'Liu|Xiangsheng|X|0000-0002-5719-2838', 'Zhou|Daojia|D|', 'Kahkoska|Anna R|AR|', 'Zhou|Zhuxian|Z|0000-0002-7104-9915', 'Meng|Huan|H|0000-0001-8844-3938', 'Buse|John B|JB|', 'Gu|Zhen|Z|0000-0003-2947-4456']
D000818:Animals D001786:Blood Glucose D003921:Diabetes Mellitus, Experimental D003924:Diabetes Mellitus, Type 2 D005947:Glucose D007328:Insulin D051379:Mice D011108:Polymers
glucose-responsive insulin diabetes drug delivery stimuli-responsive release